Voyager Therapeutics (NASDAQ:VYGR) Trading Down 2.9%

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s stock price fell 2.9% on Wednesday . The stock traded as low as $7.74 and last traded at $7.75. 163,179 shares were traded during trading, a decline of 82% from the average session volume of 927,578 shares. The stock had previously closed at $7.98.

Analysts Set New Price Targets

VYGR has been the subject of several recent research reports. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 9th. Guggenheim initiated coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They set a “buy” rating and a $22.00 target price for the company. HC Wainwright initiated coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They set a “buy” rating and a $30.00 target price for the company. Wells Fargo & Company raised Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $9.00 to $14.00 in a research report on Tuesday, January 2nd. Finally, Citigroup initiated coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They set a “buy” rating and a $16.00 target price for the company. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Voyager Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $19.33.

Voyager Therapeutics Stock Up 2.1 %

The business has a 50-day simple moving average of $8.80 and a two-hundred day simple moving average of $7.95. The stock has a market capitalization of $418.65 million, a P/E ratio of 2.44 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Wednesday, February 28th. The company reported $1.25 EPS for the quarter, topping the consensus estimate of ($0.59) by $1.84. The company had revenue of $90.06 million for the quarter, compared to analysts’ expectations of $4.95 million. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. On average, sell-side analysts forecast that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current year.

Institutional Trading of Voyager Therapeutics

Large investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. bought a new position in Voyager Therapeutics in the second quarter valued at about $30,000. Gladius Capital Management LP bought a new position in Voyager Therapeutics in the third quarter valued at about $25,000. AJOVista LLC bought a new position in Voyager Therapeutics in the fourth quarter valued at about $39,000. UBS Group AG bought a new position in Voyager Therapeutics in the first quarter valued at about $39,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Voyager Therapeutics in the fourth quarter valued at about $43,000. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.